Inside the research

United Therapeutics Corporation

UTHR Research profile · latest available data

Price overview

$475.45

▲ +3.24 (+0.7%)

52w hi$596.76
52w lo$415.34
Vol472.40K
As of25 Sep 2026

The Verdict

Hold

Our score -0.17

Short-0.44
Medium-0.08
Long+0.19

computed 2026-09-27

Key fundamentals

United Therapeutics Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

Market cap$20.39B
Enterprise value$17.73B
Trailing P/E17.66x
Forward P/E15.83x
EV / EBITDA11.85x
P / S (ttm)6.46x
Profit margin41.6%
Return on equity19.3%
Revenue growth-1.9%
Earnings growth+13.4%

Layer Breakdown

LayerRawContribution
Fundamental+0.26
Sector+0.08
Technical-0.30
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

United States · www.unither.com

Risk Metrics

Beta vs SPX0.42
Corr SPX0.16
Annual vol41.0%
Annual ret+22.8%
Sharpe0.56
Max DD-33.0%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$662.54
High / Low$750.00 / $516.00
Median$675.00
Analysts13
Strong Buy2
Buy9
Hold3
Sell0
Strong Sell0

Recent rating actions

2026-05-07Wells Fargo→ Overweight
2026-05-07RBC Capital→ Outperform
2026-04-10Morgan Stanley→ Equal-Weight
2026-03-31Wells Fargo→ Equal-Weight
2026-03-31HC Wainwright & Co.→ Buy
2026-03-31B of A Securities→ Neutral

Material Events

DateEvent8-K
2026-08-05Earnings Release, Exhibitsread
2026-07-23Officer / Director Change, Reg FD Disclosure…read
2026-06-29Officer / Director Change, Shareholder Vote…read
2026-05-06Earnings Release, Exhibitsread
2026-03-30Other Material Event, Exhibitsread
2026-03-09Material Agreement, Reg FD Disclosure…read
2026-03-02Reg FD Disclosure, Exhibitsread
2026-02-25Earnings Release, Exhibitsread
2026-01-22Officer / Director Change, Bylaws Amendment…read
2025-10-29Earnings Release, Exhibitsread
2025-09-02Other Material Event, Exhibitsread
2025-08-01Material Agreement, Reg FD Disclosure…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpOption exercise9.50K$1.29M
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell1.25K$626.60K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell1.33K$665.24K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell1.52K$762.35K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell440$221.29K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell160$80.61K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell961$485.48K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell1.68K$849.84K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell920$466.57K
2026-08-13ROTHBLATT MARTINE ADirector, Officer, ChairpSell640$325.61K

Flow & Concentration

Insider 180d net-$48.07M
Insider buys / sells0 / 117
Insider biasSellers
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-08-144view
2026-08-134view
2026-08-124view
2026-08-114view
2026-08-104view
2026-08-074view
2026-08-064view
2026-08-064view
2026-08-054view
2026-08-0510-Qview
2026-08-058-Kview
2026-08-044view
2026-08-034view
2026-07-314view
2026-07-304view

The Long Run

FY 2010–2025 · 16 years

LineLatestCAGRTrend
Revenue$2.88B+11.0%
Gross profit$2.80B+27.5%
Operating income$1.49B+33.6%
Net income$1.33B+67.5%
Cash from ops$1.56B+24.9%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$474.04$479.97$470.40$475.45472.40K
Sep 24$472.72$481.32$468.97$472.21585.50K
Sep 23$498.82$500.05$487.73$489.42433.40K
Sep 22$493.98$499.58$488.08$497.59586.40K
Sep 21$497.70$497.70$491.26$493.101.19M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →